Singer D, La EM, Dubois de Gennes C, Graham J, et al. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease. Vaccine 2026;88:128770.
PMID: 42349134